Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 12-Month Low – Should You Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.94 and last traded at $4.97, with a volume of 2844941 shares changing hands. The stock had previously closed at $5.21.

Wall Street Analysts Forecast Growth

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Trading Down 4.6 %

The company’s fifty day moving average is $6.95 and its 200-day moving average is $7.27. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. The company has a market capitalization of $19.53 billion, a PE ratio of -19.12 and a beta of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The company had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. On average, analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.